Tags

Type your tag names separated by a space and hit enter

MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson's Disease and Multiple System Atrophy.
Mol Neurobiol. 2017 Dec; 54(10):7736-7745.MN

Abstract

Parkinson's disease (PD) and multiple system atrophy (MSA) are both part of the spectrum of neurodegenerative movement disorders and α-synucleinopathies with overlap of symptoms especially at early stages of the disease but with distinct disease progression and responses to dopaminergic treatment. Therefore, having biomarkers that specifically classify patients, which could discriminate PD from MSA, would be very useful. MicroRNAs (miRNAs) regulate protein translation and are observed in biological fluids, including cerebrospinal fluid (CSF), and may therefore have potential as biomarkers of disease. The aim of our study was to determine if miRNAs in CSF could be used as biomarkers for either PD or MSA. Using quantitative PCR (qPCR), we evaluated expression levels of 10 miRNAs in CSF patient samples from PD (n = 28), MSA (n = 17), and non-neurological controls (n = 28). We identified two miRNAs (miR-24 and miR-205) that distinguished PD from controls and four miRNAs that differentiated MSA from controls (miR-19a, miR-19b, miR-24, and miR-34c). Combinations of miRNAs accurately discriminated either PD (area under the curve (AUC) = 0.96) or MSA (AUC = 0.86) from controls. In MSA, we also observed that miR-24 and miR-148b correlated with cerebellar ataxia symptoms, suggesting that these miRNAs are involved in cerebellar degeneration in MSA. Our findings support the potential of miRNA panels as biomarkers for movement disorders and may provide more insights into the pathological mechanisms related to these disorders.

Links

PMC Free PDF

Authors+Show Affiliations

Marques TM
Department of Neurology, Radboud University Medical Center and Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands. Department of Laboratory Medicine, Radboud University Medical Center, P.O. Box 9101, Nijmegen, 6500 HB, The Netherlands. Parkinson Center Nijmegen, Nijmegen, The Netherlands.
Kuiperij HB
Department of Neurology, Radboud University Medical Center and Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands. Department of Laboratory Medicine, Radboud University Medical Center, P.O. Box 9101, Nijmegen, 6500 HB, The Netherlands.
Bruinsma IB
Department of Neurology, Radboud University Medical Center and Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands. Department of Laboratory Medicine, Radboud University Medical Center, P.O. Box 9101, Nijmegen, 6500 HB, The Netherlands.
van Rumund A
Department of Neurology, Radboud University Medical Center and Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands. Parkinson Center Nijmegen, Nijmegen, The Netherlands.
Aerts MB
Department of Neurology, Radboud University Medical Center and Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands. Parkinson Center Nijmegen, Nijmegen, The Netherlands.
Esselink RAJ
Department of Neurology, Radboud University Medical Center and Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands. Parkinson Center Nijmegen, Nijmegen, The Netherlands.
Bloem BR
Department of Neurology, Radboud University Medical Center and Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands. Parkinson Center Nijmegen, Nijmegen, The Netherlands.
Verbeek MM
Department of Neurology, Radboud University Medical Center and Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands. Marcel.Verbeek@radboudumc.nl. Department of Laboratory Medicine, Radboud University Medical Center, P.O. Box 9101, Nijmegen, 6500 HB, The Netherlands. Marcel.Verbeek@radboudumc.nl. Parkinson Center Nijmegen, Nijmegen, The Netherlands. Marcel.Verbeek@radboudumc.nl.

MeSH

AgedBiomarkersFemaleHumansMaleMicroRNAsMiddle AgedMultiple System AtrophyParkinson Disease

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27844283

Citation

Marques, Tainá M., et al. "MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson's Disease and Multiple System Atrophy." Molecular Neurobiology, vol. 54, no. 10, 2017, pp. 7736-7745.
Marques TM, Kuiperij HB, Bruinsma IB, et al. MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson's Disease and Multiple System Atrophy. Mol Neurobiol. 2017;54(10):7736-7745.
Marques, T. M., Kuiperij, H. B., Bruinsma, I. B., van Rumund, A., Aerts, M. B., Esselink, R. A. J., Bloem, B. R., & Verbeek, M. M. (2017). MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson's Disease and Multiple System Atrophy. Molecular Neurobiology, 54(10), 7736-7745. https://doi.org/10.1007/s12035-016-0253-0
Marques TM, et al. MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson's Disease and Multiple System Atrophy. Mol Neurobiol. 2017;54(10):7736-7745. PubMed PMID: 27844283.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson's Disease and Multiple System Atrophy. AU - Marques,Tainá M, AU - Kuiperij,H Bea, AU - Bruinsma,Ilona B, AU - van Rumund,Anouke, AU - Aerts,Marjolein B, AU - Esselink,Rianne A J, AU - Bloem,Bas R, AU - Verbeek,Marcel M, Y1 - 2016/11/14/ PY - 2016/07/18/received PY - 2016/10/24/accepted PY - 2016/11/16/pubmed PY - 2018/7/3/medline PY - 2016/11/16/entrez KW - Biomarkers KW - Cerebrospinal fluid KW - Multiple system atrophy KW - Parkinson’s disease KW - microRNA SP - 7736 EP - 7745 JF - Molecular neurobiology JO - Mol Neurobiol VL - 54 IS - 10 N2 - Parkinson's disease (PD) and multiple system atrophy (MSA) are both part of the spectrum of neurodegenerative movement disorders and α-synucleinopathies with overlap of symptoms especially at early stages of the disease but with distinct disease progression and responses to dopaminergic treatment. Therefore, having biomarkers that specifically classify patients, which could discriminate PD from MSA, would be very useful. MicroRNAs (miRNAs) regulate protein translation and are observed in biological fluids, including cerebrospinal fluid (CSF), and may therefore have potential as biomarkers of disease. The aim of our study was to determine if miRNAs in CSF could be used as biomarkers for either PD or MSA. Using quantitative PCR (qPCR), we evaluated expression levels of 10 miRNAs in CSF patient samples from PD (n = 28), MSA (n = 17), and non-neurological controls (n = 28). We identified two miRNAs (miR-24 and miR-205) that distinguished PD from controls and four miRNAs that differentiated MSA from controls (miR-19a, miR-19b, miR-24, and miR-34c). Combinations of miRNAs accurately discriminated either PD (area under the curve (AUC) = 0.96) or MSA (AUC = 0.86) from controls. In MSA, we also observed that miR-24 and miR-148b correlated with cerebellar ataxia symptoms, suggesting that these miRNAs are involved in cerebellar degeneration in MSA. Our findings support the potential of miRNA panels as biomarkers for movement disorders and may provide more insights into the pathological mechanisms related to these disorders. SN - 1559-1182 UR - https://www.unboundmedicine.com/medline/citation/27844283/MicroRNAs_in_Cerebrospinal_Fluid_as_Potential_Biomarkers_for_Parkinson's_Disease_and_Multiple_System_Atrophy_ DB - PRIME DP - Unbound Medicine ER -